{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:46:49Z","timestamp":1771926409403,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/coc.0000000000000003","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T03:00:21Z","timestamp":1385434821000},"page":"1-7","source":"Crossref","is-referenced-by-count":23,"title":["Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma"],"prefix":"10.1097","volume":"39","author":[{"given":"Shahed N.","family":"Badiyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine O.","family":"Menias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shariq","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven M.","family":"Strasberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Linehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Myerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag J.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1200\/JCO.2012.44.7516","article-title":". Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.","volume":"31","author":"Herman","year":"2013","journal-title":"J Clin Oncol"},{"key":"R2-1-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2006.07.5663","article-title":". Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.","volume":"25","author":"Huguet","year":"2007","journal-title":"J Clin Oncol"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":". Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"R4-1-20210128","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0360-3016(95)02134-5","article-title":". Radiosensitization of pancreatic cancer cells by 2,2-difluoro-2-deoxycytidine.","volume":"34","author":"Lawrence","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.1999.17.7.2208","article-title":". Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.","volume":"17","author":"Blackstock","year":"1999","journal-title":"J Clin Oncol"},{"key":"R6-1-20210128","first-page":"2246","article-title":". Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.","volume":"7","author":"Wolff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R7-1-20210128","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1200\/JCO.2000.18.19.3384","article-title":". Eastern Cooperative Oncology Group. Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.","volume":"18","author":"Talamonti","year":"2000","journal-title":"J Clin Oncol"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2001.19.22.4202","article-title":". Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.","volume":"19","author":"McGinn","year":"2001","journal-title":"J Clin Oncol"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":". A phase III trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.","volume":"84","author":"Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-1-20210128","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":". Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R13-1-20210128","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":". FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-1-20210128","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":". Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"R17-1-20210128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2011.05.038","article-title":". Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.","volume":"99","author":"Huang","year":"2011","journal-title":"Radiother Oncol"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":". Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2006.12.053","article-title":". Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.","volume":"68","author":"Murphy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1245\/ASO.2006.03.039","article-title":". A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.","volume":"13","author":"Talamonti","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2007.13.9014","article-title":". Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.","volume":"26","author":"Small","year":"2008","journal-title":"J Clin Oncol"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/COC.0b013e3181e9c103","article-title":". A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.","volume":"34","author":"Cardenes","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00066-007-1641-1","article-title":". Concurrent chemoradiotherapy for advanced pancreatic cancer: 1000 mgm2 gemcitabine can be administered using limited-field radiotherapy.","volume":"183","author":"Yamazaki","year":"2007","journal-title":"Strahlenther Onkol"},{"key":"R24-1-20210128","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archsurg.2009.282","article-title":". Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival.","volume":"145","author":"Fatima","year":"2010","journal-title":"Arch Surg"},{"key":"R27-1-20210128","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1007\/s00464-010-1552-6","article-title":". Biliary metal stents are superior to plastic stents for preoperative biliary decompression in pancreatic cancer.","volume":"25","author":"Decker","year":"2011","journal-title":"Surg Endosc"},{"key":"R28-1-20210128","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":". DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"R29-1-20210128","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1200\/JCO.2010.33.8038","article-title":". Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.","volume":"29","author":"Crane","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:57:43Z","timestamp":1620950263000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201602000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000003","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}